公开(公告)号：WO2023086995A2

公开(公告)日：2023-05-19

申请号：PCT/US2022/079820

申请日：2022-11-14

Applicant: IMANIS LIFE SCIENCES, LLC ,  RUSSELL, Stephen J. ,  FIOS THERAPEUTICS LLC

Inventor： MCGREGOR, Christopher G. A. ,  KROTOVA, Karina

IPC: C12N15/85 ,  A61K35/12

Abstract: Provided herein are genetically modified ungulate cells expressing a chimeric antigen receptor. Also provided herein are transgenic ungulate cells that can be used as cell carriers for the delivery of oncolytic viruses in cancer therapy. Also provided are transgenic ungulates comprising these cells, methods of making these cells, and methods of treating cancer by administering these cells to a subject in need thereof. Also provided are transgenic ungulate cells that express a chimeric antigen receptor and uses thereof.

公开(公告)号：WO2023086988A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/079809

申请日：2022-11-14

Applicant: FRED HUTCHINSON CANCER CENTER

Inventor： TAPSCOTT, Stephen J. ,  SPENS, Amy Elizabeth ,  HAMM, Danielle Christine ,  BRADLEY, Robert, K.

IPC: A61K35/12 ,  A61K35/17 ,  C12N5/071 ,  A61P21/00 ,  C12N15/85

Abstract: The current disclosure provides novel methods and compositions to suppress immunity and are useful for treating autoimmune and inflammatory conditions, and in some circumstances, cancers. Accordingly, aspects of the disclosure relate to a method for treating an inflammatory, autoimmune, autoinflammatory or cancer disease or condition in a subject comprising administering a DUX4 polypeptide or nucleic acid encoding a DUX4 polypeptide to the subject. Further aspects relate to a method for treating a tissue transplant subject, the method comprising administering a DUX4 polypeptide or nucleic acid encoding a DUX4 polypeptide to the subject. The present inventions also relate to universal donor stem cells that overcome immune rejection in cell-based transplantation therapies.

公开(公告)号：WO2023081815A1

公开(公告)日：2023-05-11

申请号：PCT/US2022/079293

申请日：2022-11-04

Applicant: SALIOGEN THERAPEUTICS, INC.

Inventor： HIGGINS, Joseph J. ,  TABIBIAZAR, Ray ,  HARANDI, Omid F. ,  HEMPHILL, James B.

IPC: A61K35/12 ,  A61K48/00

Abstract: Methods of making stem cells, for instance with an enzyme capable of performing targeted genomic integration. The method involves obtaining a stem cell from a biological sample; and transfecting the stem cell with a first nucleic acid encoding an enzyme capable of performing targeted genomic integration, wherein the first nucleic acid is RNA, and a second, non-viral nucleic acid encoding a donor DNA comprising a transgene and flanked by ends recognized by the enzyme. The method also involves reprogramming the transfected somatic cell to produce a pluripotent stem cell comprising the transgene in a certain genomic locus and/or site.

公开(公告)号：WO2023077015A2

公开(公告)日：2023-05-04

申请号：PCT/US2022/078803

申请日：2022-10-27

Applicant: IOVANCE BIOTHERAPEUTICS, INC.

Inventor： VOGT, Frederick, G. ,  LAM, Binh ,  CHANG, Jennifer ,  REPACZKI-JONES, Ramona

IPC: G16H10/40 ,  G16H40/20 ,  G16H80/00 ,  A61K35/12 ,  A61K35/17

Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.

公开(公告)号：WO2023076882A1

公开(公告)日：2023-05-04

申请号：PCT/US2022/078633

申请日：2022-10-25

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Inventor： HE, Mei

IPC: A61K47/34 ,  A61K35/12 ,  A61P35/00 ,  C08L67/02

Abstract: Developing therapeutic cancer vaccines to modulate immune responses for cancer treatment has gained increasing interest. However, to date, such cancer vaccines suffer from weak immunogencity, low specificity, and off-target effects. Developing novel cancer vaccines is needed for precise control of anti-tumor immune responses. Described are polymeric micelle nanoparticles and their use in producing extracellular vesicles containing a cargo molecule, The cargo-loaded extracellular vesicles can be used as therapeutic delivery vectors.

公开(公告)号：WO2023038899A1

公开(公告)日：2023-03-16

申请号：PCT/US2022/042645

申请日：2022-09-06

Applicant: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL

Inventor： CASSADY, Kevin A. ,  SAINI, Uksha ,  CHANDLER, Dawn ,  WANG, Ruoning ,  WEIN, Nico

IPC: A61K35/12 ,  C07K16/30 ,  C12N5/16 ,  C07K14/435 ,  A61K9/127

Abstract: This disclosure relates to populations and compositions of purified cancer cell-derived vesicles and uses thereof.

公开(公告)号：WO2023034894A1

公开(公告)日：2023-03-09

申请号：PCT/US2022/075809

申请日：2022-09-01

Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Inventor： SYKES, Megan ,  YANG, Yong-Guang

IPC: A61K35/12 ,  A61K38/17 ,  A61P37/06

Abstract: Provided herein are methods of xenotransplantation, for example, porcine to human transplantation. Also provided herein are extracellular vesicles ("EVs", e.g., exosomes) and compositions comprising the same, e.g. EVs expressing human CD47. Further provided herein are methods of making EVs and use thereof for xenotransplantation. In some aspects, the methods of xenotransplantation comprise steps of expressing human CD47 on xenografts.

公开(公告)号：WO2023033761A1

公开(公告)日：2023-03-09

申请号：PCT/TR2022/050845

申请日：2022-08-11

Applicant: OVALI, Ercüment ,  BAĞIŞ, Halil Tayfun

Inventor： TAŞTAN, Cihan ,  TÜMENTEMUR, Gamze

IPC: A61K35/12 ,  C12N5/00 ,  C12N15/87

Abstract: The invention relates to the macropinocytosis-mediated mitochondrial transplantation developed with the purpose of increasing the meiosis simulation, oocyte maturation and the quality of mature oocytes in clinical applications. In order to achieve this, the method subject to the invention comprises the steps of transplantation mediated with macropinocytosis as a result of PBMC isolation on blood (1), mitochondria isolation (2), marking of the isolated mitochondria (3) and evaluation of concentration, characterized by comprising; the step of the transplantation of the isolated mitochondria (3) mediated by macropinocytosis, by incubating with GV (Germinal Vesicle) oocytes at meiosis 1 phase and oocytes at meiosis 2 phase (5, 6).

公开(公告)号：WO2023023538A2

公开(公告)日：2023-02-23

申请号：PCT/US2022/075051

申请日：2022-08-17

Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Inventor： WEYAND, Cornelia M. ,  GORONZY, Joerg J. ,  WU, Bowen

IPC: A61K35/17 ,  C12N5/0783 ,  A61K35/12 ,  A61K41/00

Abstract: This document provides methods and materials involved in treating mammals (e.g., humans) having tissue inflammation (e.g., autoimmune tissue inflammation). For example, one or more inhibitors of production of a tumor necrosis factor-α (TNF-α) polypeptide by, for example, T cells can be administered to a mammal (e.g., a human) having tissue inflammation (e.g., autoimmune tissue inflammation) to treat the mammal.

公开(公告)号：WO2023284742A1

公开(公告)日：2023-01-19

申请号：PCT/CN2022/105212

申请日：2022-07-12

Applicant: WESTLAKE THERAPEUTICS (HANGZHOU) CO. LIMITED

Inventor： GAO, Xiaofei ,  HUANG, Yanjie ,  LIU, Xuan ,  NIE, Xiaoqian

IPC: A61K35/12 ,  A61K39/00 ,  C12N1/00 ,  C12N5/07 ,  C12Q1/04 ,  C12Q1/48

Abstract: Provided is a cell having an agent linked thereto, wherein the agent is linked to at least one membrane protein of the cell via a linker comprising a N-terminal glycine through sortase recognition motif. Also provided is a method for obtaining the modified cell, as well as the use of the modified cells for delivering agents such as drugs and probes.